Effect of Dapagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on Vascular Function in Patients with Type 2 Diabetes Compared with Gliclazide | American Diabetes Association

View our Privacy Policy & Terms of Use

This free content is available to registered users.

Becoming a Registered User only requires your name and email address.

Login Register Now for Your Free Account

Effect of Dapagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, on Vascular Function in Patients with Type 2 Diabetes Compared with Gliclazide

Speaker: Soo Lim

Session: Links between Diabetes and Cardiovascular Disease

Congress: 79th Scientific Sessions